Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Papp KA, et al. Among authors: krueger jg. N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017. N Engl J Med. 2017. PMID: 28423301 Free article. Clinical Trial.
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM. Krueger GG, et al. Among authors: krueger jg. J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):281-5. doi: 10.1067/mjd.2000.106374. J Am Acad Dermatol. 2000. PMID: 10906652
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.
Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR. Papp K, et al. Among authors: krueger jg. J Am Acad Dermatol. 2001 Nov;45(5):665-74. doi: 10.1067/mjd.2001.117850. J Am Acad Dermatol. 2001. PMID: 11606914 Clinical Trial.
Analytical approaches to reporting long-term clinical trial data.
Papp KA, Fonjallaz P, Casset-Semanaz F, Krueger JG, Wittkowski KM. Papp KA, et al. Among authors: krueger jg. Curr Med Res Opin. 2008 Jul;24(7):2001-8. doi: 10.1185/03007990802215315. Epub 2008 Jun 4. Curr Med Res Opin. 2008. PMID: 18534049 Free PMC article.
Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis.
Wittkowski KM, Leonardi C, Gottlieb A, Menter A, Krueger GG, Tebbey PW, Belasco J, Soltani-Arabshahi R, Gray J, Horn L, Krueger JG; International Psoriasis Council. Wittkowski KM, et al. Among authors: krueger jg, krueger gg. PLoS One. 2011;6(6):e20279. doi: 10.1371/journal.pone.0020279. Epub 2011 Jun 1. PLoS One. 2011. PMID: 21673809 Free PMC article.
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S. Papp KA, et al. Among authors: krueger jg. N Engl J Med. 2012 Mar 29;366(13):1181-9. doi: 10.1056/NEJMoa1109017. N Engl J Med. 2012. PMID: 22455412 Free article. Clinical Trial.
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.
Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB, Martin DA. Papp KA, et al. Among authors: krueger jg. J Invest Dermatol. 2012 Oct;132(10):2466-2469. doi: 10.1038/jid.2012.163. Epub 2012 May 24. J Invest Dermatol. 2012. PMID: 22622425 Free article. Clinical Trial. No abstract available.
465 results